$ALKS

Why is Alkermes stock sliding today? By Investing.com

Alkermes (ALKS) shares fell 5.2% pre-market to $50 after Q2 2026 results. Adjusted EPS was $0.00 vs -$0.02 expected, and revenue rose to $496M vs $459M forecast. Full-year 2026 revenue guidance midpoint was $1.785B vs $1.81B consensus. Piper Sandler raised its price target to $65 from $43.

Original reporting
Published Jul 28, 2026, 1:10 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 28, 2026, 1:15 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$ALKS
Bearish
medium confidence
Mentioned
$ALKS
Relevance
8/10
alphai data visualization · based on investing.com
Decision brief

The 30-second read

$ALKSBearishMed
01

Why it matters

Investors appear to be repricing the stock based on the full-year 2026 revenue guidance midpoint coming in below consensus, turning a beat into a near-term headwind.

02

Market read

The actionable takeaway is the guidance midpoint shortfall versus consensus, which is driving the immediate sell-off and may influence near-term positioning given prior YTD strength and short interest.

03

What to watch

Short interest (~10.7% of float) and a crowded long position may exaggerate the move; integration costs from the Avadel deal could be temporary rather than structural.

Relevance 8/10Novelty 6/10Timing: pre-market today after Alkermes released Q2 2026 results and guidance before the open

Background

Alkermes’ Q2 2026 print included a revenue beat and EPS beat, with LUMRYZ franchise contribution following the earlier Avadel acquisition.

Company-level read

Ticker impact

$ALKSBearishMedium confidence
Context

Alkermes shares fell 5.2% pre-open after Q2 results beat EPS and revenue, but the full-year 2026 revenue guidance midpoint missed consensus.

Expected impact

Near-term pressure likely persists until investors digest the guidance gap and any follow-up commentary on integration costs and LUMRYZ ramp.

Evidence & confidence

The article cites a below-consensus guidance midpoint ($1.785B vs $1.81B) as the catalyst for the sell-off, alongside elevated YTD gains and short interest that can amplify profit-taking.

Market effects

Could modestly affect sentiment toward specialty pharma/narcolepsy franchise names if investors generalize guidance conservatism.

Limited evidence of broad index-driven selling; article frames weakness as company-specific.

Primarily US-focused read-through via Nasdaq/S&P context; no direct global catalyst cited.

Counterpoint

The revenue and EPS beat plus a raised Piper Sandler price target ($65) could mean the guidance miss is more about conservatism than deteriorating fundamentals.

Key entities

  • Alkermes

    Subject of the article; pre-open shares down 5.2% after Q2 results and guidance midpoint miss.

  • LUMRYZ

    Narcolepsy-focused franchise cited as contributing to the revenue beat, but integration costs and tempered outlook weigh on sentiment.

  • Avadel Pharmaceuticals

    Acquisition of Avadel completed earlier this year, linked to LUMRYZ contribution and integration-cost concerns.

  • Piper Sandler

    Raised price target to $65 from $43 and maintained Overweight, offering a supportive counterpoint.

Related articles

$ALKSMed

Alkermes plc Q2 2026 Earnings Call Summary

Strategic Evolution and Operational Context Management characterized the current period as a major phase of growth, with the orexin platform evolving from a hypersomnolence focus to a broad neurocircuitry platform for ADHD and fatigue. Alixorexton is positioned as a leading asset, being the only orexin 2 receptor agonist to demonstrate efficacy and tolerability across both NT1 and NT2 in large Phase 2 studies.

$ALKSMedAI 8/10

Alkermes plc. (ALKS): Results of Operations and Financial Condition

Alkermes plc. (ALKS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 alks-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Alkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Katie Joyce +1 781 249 8927 Alkermes plc Reports Second Quarter 2026 Financial Results — Second Quarter Revenues of $496.0 Million — — GAAP Net Income

$ALKSMed

Interim Analysis: Sustained Wakefulness with Alixorexton in Narcolepsy

Alkermes plc reported interim results from a long-term extension study of alixorexton in adults with narcolepsy type 1 and type 2. At week 24, alixorexton showed sustained improvements on the Maintenance of Wakefulness Test and Epworth Sleepiness Scale, with mean MWT sleep latency about 29 minutes (NT1) and 18 minutes (NT2) and mean ESS about 7.5 (NT1) and 8.9 (NT2). No serious treatment-emergent adverse events were reported.

$ALKSMed

First MS Mobility Drug Gets Green Light From NHS England

NHS England said it will make fampridine (Fampyra), a pill for adults with multiple sclerosis-related walking impairment, routinely available on the NHS after a Clinical Priorities Advisory Group review. NHSE cited trials showing improved walking speed in 43% of patients and about a 25% speed increase, with ~5,000 eligible patients in England in year one. The decision follows a 2022 NICE cost-effectiveness refusal and the expiry of the Fampyra brand patent.

$AZNMed

Biotech and Pharma Industry News | BioPharma Dive

BioPharma Dive roundup covers AstraZeneca’s eplontersen failure in a major heart disease study, boosting expectations for rival TTR amyloidosis drugs from Alnylam and BridgeBio. Other items include ARPA-H funding, GSK ending a neuroscience alliance with Alector, Vera Therapeutics’ FDA nod for IgA nephropathy, and Vertex’s $10B plan to buy Crinetics.